NCT03416478

The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer

The Implication of Plasma Circulating Tumor DNA (ctDNA) in the Recurrence Surveillance of Stage II and III Colorectal Cancer: a Prospective Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate circulating tumor DNA (ctDNA) as a predictive and surveillant method for tumor recurrence in stage II and III colorectal cancer (CRC).

Detailed description

This study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of a short-term disease recurrence in surgical resective stage II and stage III colorectal cancer (CRC). The investigators will recruit newly diagnosed CRC patients, systematically collect their blood samples at the following time point: before surgery, one week after surgery, every three months for the first year and every six months for the second year, which are coincidence with the recommended clinical follow-up. Patients' outcome and survival will be tracked. These study will permit assessment of ctDNA as a predictive and surveillant method for a short-term (two years) tumor recurrence in comparison with other parameters.

Conditions

• Colorectal Cancer
• ctDNA
• Surveillance

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	ctDNA test	ctDNA test to find some possible mutation.

Timeline

• Start date: 2018-01-01
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2018-01-31
• Last updated: 2018-02-01

Locations

1 site across 1 country: China